Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge DOI Creative Commons
Karolina Wąsik, Sebastian Tomaszuk, Magda Wojtuś

et al.

Journal of Education Health and Sport, Journal Year: 2023, Volume and Issue: 50(1), P. 62 - 75

Published: Dec. 30, 2023

Introduction and purpose: Nowadays, when mental disorders are considered by the World Health Organisation as a global burden, potential usage of psychedelic drugs supportive therapy is gaining more attention worldwide. The aim this paper to summarize usefulness psilocybin - representative psychedelics in psychiatric venues. In review we describe its properties, efficacy adverse events treating depression, trauma obsessive-compulsive disorders. Brief description state knowledge: Psilocybin demonstrates safety profile which does not differ from standard used therapies disorders. Positive results administration were noticed on different scales clinically meaningful. With depression being most common disease growing demand for new remedies, conducted research concentrated subject, but there also some evidence purpose treatment Conclusions: merits further foregoing studies pointing efficacy. Psychedelic-assisted may create noteworthy opportunities current matter possibility that future cases they will be first line treatment. Nevertheless, still data needed determine placement treatments.

Language: Английский

The Emergence of Psilocybin in Psychiatry and Neuroscience DOI Creative Commons
Hossein Omidian,

Alborz Omidian

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 555 - 555

Published: April 9, 2025

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile. Emerging evidence supports efficacy conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, limited population diversity trials. Advances biosynthetic production optimized psychotherapeutic integration are necessary to ensure scalability accessibility. Future should focus long-term safety, dosing precision, neurobiological mechanisms refine therapeutic applications. provides critical foundation advancing evidence-based of psilocybin.

Language: Английский

Citations

1
The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects DOI Creative Commons

Kush Bhatt,

Cory R. Weissman

npj Mental Health Research, Journal Year: 2024, Volume and Issue: 3(1)

Published: Feb. 20, 2024

Abstract Psilocybin is a serotonergic psychedelic shown to have enduring antidepressant effects. Currently, the mechanism for its effects not well understood. Empathy and prosocial behavior may be important understanding therapeutic benefit of psilocybin. In this article we review effect psilocybin on empathy behavior. Moreover, propose that induce positive feedback loop involving which helps explain observed,

Language: Английский

Citations

7
Psilocybin for the treatment of Alzheimer’s disease DOI Creative Commons
Siyi Zheng,

Rong Ma,

Yang Yang

et al.

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 18

Published: July 10, 2024

Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency innovative treatment modalities. Psilocybin, psychoactive alkaloid intrinsic hallucinogenic mushrooms, has garnered attention within neuropsychiatric realm due its established safety efficacy in treating depression. Nonetheless, potential therapeutic avenue remains largely uncharted. This comprehensive review endeavors encapsulate pharmacological effects psilocybin while elucidating existing evidence concerning mechanisms contributing positive impact on AD. Specifically, active metabolite psilocybin, psilocin, elicits through modulation 5-hydroxytryptamine 2A receptor (5-HT2A receptor). causes heightened neural plasticity, diminished inflammation, improvements cognitive functions such creativity, flexibility, emotional facial recognition. Noteworthy is psilocybin’s promising role mitigating anxiety depression symptoms patients. Acknowledging attendant adverse reactions, we proffer strategies aimed at tempering or effects. Moreover, broach ethical legal dimensions inherent exploration treatment. By traversing these avenues, We propose nuanced management disease.

Language: Английский

Citations

7
Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings DOI Creative Commons
Terence H. W. Ching,

Lucia Amoroso,

Calvin Bohner

et al.

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 9, 2024

Background To date, few randomized controlled trials of psilocybin with non-directive support exist for obsessive-compulsive disorder (OCD). Results and participant feedback from an interim analysis ongoing single-dose trial (NCT03356483) converged on the possibility administering a higher fixed dose and/or more doses in future presumably greater benefits. Objectives This aims to evaluate safety, feasibility, tolerability, clinical effects two paired treatment OCD. also seeks examine whether lead OCD symptom reduction than single dose, elucidate psychological mechanisms underlying Design A (1:1), waitlist-controlled design blinded ratings will be used oral vs. waitlist control symptoms. An adaptive selection strategy implemented (i.e., first dose: 25 mg; second or 30 mg). Methods single-site enroll adult participants treatment-refractory Aside tolerability metrics, primary outcomes include symptoms assessed Yale-Brown Obsessive-Compulsive Scale – Second Edition (Y-BOCS-II). independent rater assess at baseline endpoint end dosing week. Participants followed up 12 months post-second dosing. rescreened after 7 weeks post-randomization, begin their delayed phase thereafter if still eligible. Ethics Written informed consent obtained participants. The institutional review board has approved this (protocol v. 1.7; HIC #2000032623). Discussion study advance our ability treat refractory OCD, catalyze research seeking optimize process through understanding relevant mechanisms. Clinical registration : ClinicalTrials.gov , identifier NCT05370911.

Language: Английский

Citations

4
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects DOI
Carrie Cuttler, Amanda Stueber,

Jonathan J. Simone

et al.

Journal of Psychoactive Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: Jan. 29, 2025

The ever-changing landscape surrounding legality and accessibility of psychedelics their increasing popularity make it imperative to better understand the nature psychedelic use by general population. To this end, 1,486 eligible respondents (Mage = 29.58, 67.1% male) residing in United States completed an online survey designed assess types used, methods administration dosing, frequency use, intentions for context/environments which they are perceived acute effects, those effects distress about them, residual them. Respondents predominantly endorsed using MDMA, LSD, DMT, psilocybin. predominant were oral. Most reported recreational purposes. most hallucinations, increased heart rate, positive mood, visual tracers, while headaches/migraine, dry mouth, nausea, anxiety. Participants distressed negative mood states, vomiting, nausea when under psychedelics, but mean ratings low. These results can help inform clinical trials, reform policy regarding legal access track changes these metrics as sociocultural landscapes continue shift.

Language: Английский

Citations

0
«Psychedelics, OCD and Related Disorders: Setting Methodological Strategies for Future Studies» DOI

Rodolfo Leuzzi,

Giovanni Tardivo, Luca Pellegrini

et al.

Journal of Obsessive-Compulsive and Related Disorders, Journal Year: 2025, Volume and Issue: unknown, P. 100951 - 100951

Published: March 1, 2025

Language: Английский

Citations

0
Psilocybin in pharmacotherapy of obsessive-compulsive disorder DOI Creative Commons

Maja Owe-Larsson,

Katarzyna Kamińska, Barbara Buchalska

et al.

Pharmacological Reports, Journal Year: 2024, Volume and Issue: 76(5), P. 911 - 925

Published: Aug. 1, 2024

Abstract Obsessive-compulsive disorder (OCD) is a chronic mental disease that affects approximately 2% of the population. Obsessions and compulsions are troublesome for patients may disturb their everyday activities. The pathogenesis this still not fully elucidated, but dysfunctions serotonin-, dopamine- glutamate-mediated neurotransmission together with early maladaptive schemas seem importance. Pharmacological treatment includes drugs affecting serotoninergic, dopaminergic, glutamatergic systems, such as selective serotonin reuptake inhibitors (SSRIs). Providing up to 40% OCD resistant currently available medications, there need novel effective therapies. Recent discoveries suggest psilocybin, non-physically addictive psychoactive substance, ameliorate symptoms. When used in appropriate doses under strict clinical control, psilocybin appears valuable OCD. This narrative article provides thorough overview OCD’s etiology, current options, emerging evidence supporting psilocybin’s efficacy managing

Language: Английский

Citations

2
Cognitive inflexibility, obsessive-compulsive symptoms and traits and poor post-pandemic adjustment DOI Creative Commons
Ana Maria Frota Lisbôa Pereira de Souza, Luca Pellegrini, Naomi Fineberg

et al.

Neuroscience Applied, Journal Year: 2024, Volume and Issue: 3, P. 104073 - 104073

Published: Jan. 1, 2024

The ability to flexibly adapt thoughts and behaviours represents a fundamental attribute for behavioural success. Impairments in aspects of cognitive flexibility are found as transdiagnostic latent phenotypes obsessive-compulsive symptomatology present within range mental disorders the population at large. In this narrative review, we focus on attentional set-shifting aspect inflexibility, which has been largely investigated context spectrum is thought underpin perseverative symptomatology. We appraise published literature relating putative neurobiological mechanisms, methods assessment, interventional approaches, health wellbeing impacts. discuss critical knowledge gaps, promising new research avenues, potential approaches from clinical public perspective. conclude that inflexibility relevance clinicians terms understanding outcomes tailoring personalised forms treatments, professionals rigid attitudes adjustment current post-pandemic environment.

Language: Английский

Citations

1
Mechanisms of therapeutic change after psychedelic treatment in OCD DOI
Gayle Maloney, Terence H. W. Ching,

Stephen A. Kichuk

et al.

Psychiatry Research, Journal Year: 2024, Volume and Issue: 336, P. 115907 - 115907

Published: April 7, 2024

Language: Английский

Citations

0
A single dose of psilocybin induces lasting changes in metabolic connectivity within biologically informed rat brain networks related to compulsions and anxiety. DOI Open Access
Frederik Gudmundsen,

Julia Czurylo,

Camilla Trang Vo

et al.

Published: May 28, 2024

Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psychedelics last only a few hours, positive therapeutic can persist long after single administration. produce their by activating serotonin 2A receptors, but they differ other pharmacological aspects. To guide safest and most effective treatment specific disorders, it is crucial to gain better understanding distinct long-term on living brain. Here we demonstrate how three different serotonergic psychedelics; psilocybin, LSD 2C-B, induce patterns rat brain metabolic activity connectivity. The doses administered were chosen reflect humans. We found that, psilocybin induced pattern effects, particularly focusing changes connectivity between cortical regions such as orbitofrontal, medial prefrontal, insula cortex, well with dorsal striatum, thalamus, hippocampus. In contrast, 2C-B showed more similar impacts centered inhibition anterior cingulate cortex. This was accompanied increased amygdala hypothalamus, along heightened dopamine cell-rich ventral tegmental area substantia nigra. Our findings within networks provide new insights into shared drug-selective mechanisms underlying substances These could offer guidance which might be beneficial certain psychiatric diseases.

Language: Английский

Citations

0